Rifabutin: A Repurposing Candidate for Lung Disease.
作者信息
Dick Thomas
机构信息
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, United States.
Department of Medical Sciences, Hackensack Meridian School of Medicine at Seton Hall University, Nutley, NJ, United States.
出版信息
Front Microbiol. 2020 Feb 27;11:371. doi: 10.3389/fmicb.2020.00371. eCollection 2020.
Abstract
摘要
相似文献
1
Rifabutin: A Repurposing Candidate for Lung Disease.
Front Microbiol. 2020 Feb 27;11:371. doi: 10.3389/fmicb.2020.00371. eCollection 2020.
2
Rifabutin Suppresses Inducible Clarithromycin Resistance in by Blocking Induction of and .
Antibiotics (Basel). 2020 Feb 10;9(2):72. doi: 10.3390/antibiotics9020072.
3
Rifabutin Is Active against Mycobacterium abscessus Complex.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
4
and Intracellular Activity of Imipenem Combined with Rifabutin and Avibactam against Mycobacterium abscessus.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00623-18. Print 2018 Aug.
5
Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00283-18. Print 2018 Aug.
6
Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Complex.
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02234-18. Print 2019 Apr.
7
Activity of Rifabutin and Hemi-synthetic Derivatives Against Mycobacterium abscessus.
Med Chem. 2018;14(4):394-399. doi: 10.2174/1573406414666171204102633.
8
and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against .
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.01915-18. Print 2019 Apr.
9
Teicoplanin - Tigecycline Combination Shows Synergy Against .
Front Microbiol. 2018 May 11;9:932. doi: 10.3389/fmicb.2018.00932. eCollection 2018.
10
Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar.
J Antimicrob Chemother. 2016 Aug;71(8):2208-12. doi: 10.1093/jac/dkw130. Epub 2016 May 4.
引用本文的文献
1
In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of .
Antibiotics (Basel). 2025 May 10;14(5):486. doi: 10.3390/antibiotics14050486.
2
Comparison of Compartmental and Non-Compartmental Analysis to Detect Biopharmaceutical Similarity of Intravenous Nanomaterial-Based Rifabutin Formulations.
Pharmaceutics. 2023 Apr 17;15(4):1258. doi: 10.3390/pharmaceutics15041258.
3
Why Matter Matters: Fast-Tracking Drug Discovery.
Molecules. 2022 Oct 17;27(20):6948. doi: 10.3390/molecules27206948.
4
Addressing antimicrobial resistance with the IDentif.AI platform: Rapidly optimizing clinically actionable combination therapy regimens against nontuberculous mycobacteria.
Theranostics. 2022 Sep 25;12(16):6848-6864. doi: 10.7150/thno.73078. eCollection 2022.
5
Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice.
Tuberculosis (Edinb). 2022 Dec;137:102268. doi: 10.1016/j.tube.2022.102268. Epub 2022 Oct 4.
6
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
本文引用的文献
1
Rifabutin Suppresses Inducible Clarithromycin Resistance in by Blocking Induction of and .
Antibiotics (Basel). 2020 Feb 10;9(2):72. doi: 10.3390/antibiotics9020072.
2
Rifabutin Is Active against Mycobacterium abscessus in Mice.
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
3
Repositioning rifamycins for Mycobacterium abscessus lung disease.
Expert Opin Drug Discov. 2019 Sep;14(9):867-878. doi: 10.1080/17460441.2019.1629414. Epub 2019 Jun 14.
4
pulmonary disease: individual patient data meta-analysis.
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.01991-2018. Print 2019 Jul.
5
Advancing Translational Science for Pulmonary Nontuberculous Mycobacterial Infections. A Road Map for Research.
Am J Respir Crit Care Med. 2019 Apr 15;199(8):947-951. doi: 10.1164/rccm.201807-1273PP.
6
NTM drug discovery: status, gaps and the way forward.
Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7.
7
Mycobacterium abscessus WhiB7 Regulates a Species-Specific Repertoire of Genes To Confer Extreme Antibiotic Resistance.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01347-17. Print 2017 Nov.
8
Rifabutin Is Active against Mycobacterium abscessus Complex.
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
9
Rifabutin: where do we stand in 2016?
J Antimicrob Chemother. 2016 Jul;71(7):1759-71. doi: 10.1093/jac/dkw024. Epub 2016 Mar 23.
10
A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.
Antimicrob Agents Chemother. 2009 Apr;53(4):1367-76. doi: 10.1128/AAC.01275-08. Epub 2009 Jan 26.
Zotero 插件